02 February 2010,London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC:
ATSMY) notifies the market that the Company's issued share capital consists of
626,115,192 ordinary shares with voting rights. Antisoma does not hold any
ordinary shares in Treasury.

Therefore, the total number of voting rights in Antisoma is 626,115,192.

The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, Antisoma under the FSA's
Disclosure and Transparency Rules.


Enquiries:
Alison Saville
Senior Marketing and Communications Executive
Antisoma plc
+44 (0)20 3249 2144


Background on Antisoma

Antisoma is a London Stock Exchange-listed biopharmaceutical company that
develops novel products for the treatment of cancer. The Company has operations
in the UK and the US. Please visit www.antisoma.com <

http://www.antisoma.com/>
for further information about Antisoma.


[HUG#1379553]